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A B S T R A C T
In this work nasal powder formulations of thalidomide were designed and studied to be used by persons
affected by hereditary hemorrhagic telangiectasia as a complementary anti-epistaxis therapy, with the
goal of sustaining the effect obtained with thalidomide oral treatment after its discontinuation for
adverse effects. Three nasal powders were prepared using as carriers b-CD or its more hydrophilic
derivatives such as hydropropyl-b-CD and sulphobutylether-b-CD and tested with respect to
technological and biopharmaceutical features after emission with active and passive nasal powder
devices. For all formulated powders, improved dissolution rate was found compared to that of the raw
material, making thalidomide promptly available in the nasal environment at a concentration favouring
an accumulation in the mucosa. The very limited transmucosal transport measured in vitro suggests a low
likelihood of signiﬁcant systemic absorption. The topical action on bleeding could beneﬁt from the poor
absorption and from the fact that about 2–3% of the thalidomide applied on the nasal mucosa was
accumulated within the tissue, particularly with the b-CD nasal powder.
ã 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Hereditary hemorrhagic telangiectasia (HHT) is a rare genetic
disease characterized by vascular malformations with a prevalence
of about 1–2 in 10,000 individuals (Govani and Shovlin, 2009). HHT
is caused by mutations in genes encoding proteins mostly
expressed in vascular endothelial cells. These proteins are involved
in transforming the growth factor-beta superfamily signallingAbbreviations: AVMs, arteriovenous malformations; HHT, hereditary hemor-
rhagic telangiectasia; SNES, simulated nasal electrolyte solution; THAL, thalido-
mide.
* Corresponding author.
E-mail address: alessandra.rossi@unipr.it (A. Rossi).
http://dx.doi.org/10.1016/j.ijpharm.2016.07.002
0378-5173/ã 2016 The Authors. Published by Elsevier B.V. This is an open access articlpathway. Clinical manifestations include arteriovenous malforma-
tions (AVMs), which can be classiﬁed as small telangiectases
(regions of capillary dilation) and large AVMs, where arterioles and
venules are directly connected with no capillaries in between. In
particular, small telangiectases are typical of the nasal septum, oral
mucosa and gastrointestinal tract, whereas large AVMs mainly
occur in the lung, brain and liver. As these lesions are due not only
to an expansion of the vascular lumen, but also to thinning of the
vascular wall, they cause chronic nasal and/or gastrointestinal
bleeding and severe anaemia. Indeed, recurrent epistaxis is the
most common manifestation of nasal HHT and begins by the age of
10–20 years in many patients, increasing in severity with ageing.
Epistaxis may be so severe as to require blood transfusions and oral
iron supplementation (Guttmacher et al., 1995).e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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epithelium with skin, laser ablation, topical application of anti-
inﬂammatory drugs or manipulation of the coagulation and
ﬁbrinolytic pathways (Guttmacher et al., 1995). However, these
options do not permanently resolve bleeding and are not well
accepted by patients. Recent in vivo studies showed that oral
administration of thalidomide reduced the frequency and duration
of nose bleeds in HHT patients (Invernizzi et al., 2015; Lebrin et al.,
2010). The anti-angiogenic and anti-hemorrhagic activities of
thalidomide are due not only to a direct inhibition of endothelial
cell proliferation and migration, but also to an increase in mural
cell coverage, which stabilizes blood vessels and prevents bleeding.
However, the observed anti-epistaxis effect of thalidomide is
reversible and nose bleeding recurs after discontinuation of the
oral treatment. Thus, systemic administration must be resumed, at
the risk of causing adverse effects, such as reversible neuropathy,
constipation and sedation (von Moos et al., 2003).
When HHT involves the nasal mucosa, the topical administra-
tion of thalidomide inside the nasal cavity for a maintenance
treatment, complementing the systemic administration, is a
therapeutic hypothesis. Thalidomide is practically insoluble in
water and undergoes rapid and spontaneous hydrolysis in an
aqueous environment (Goosen et al., 2002; Pereira et al., 2013).
Therefore, thalidomide should be formulated as dry powder for
insufﬂation, to increase physico-chemical and microbiological
stability (Vidgren and Kublik, 1998) as well as drug concentration
on and contact time with the nasal mucosa (Colombo et al., 2011;
Jiang et al., 2010).
However, the performance of a powder formulation for nasal
delivery will be highly dependent on drug dissolution rate in the
liquid lining the nasal mucosa. Complexation with b-cyclodextrins
(b-CDs) has been described as increasing thalidomide aqueous
solubility (Kratz et al., 2012; Krenn et al., 1992). b-CD has proven to
be an excellent solubility and absorption enhancer in nasal drug
delivery (Challa et al., 2005; De Ascentiis et al., 1996; Merkus et al.,
1999), being the most used in pharmaceutical applications since its
cavity size is suitable for many drugs. Some b-CD derivatives used
in topical drug formulations, such as hydroxypropyl-b-CD (HP-
b-CD) and sulphobutylether-b-CD (SBE-b-CD), have higher water
solubility and a better toxicological proﬁle than b-CD (Badr-Eldin
et al., 2008; de Araujo et al., 2008; Fukuda et al., 2008; Loftsson and
Masson, 2001; Marttin et al., 1998).
Hence, in this work novel nasal powder formulations of
thalidomide were studied to enable thalidomide administration
in the nose and provide HHT patients treated by oral thalidomideTable 1
Conditions of the HPLC methods used.
Conditions Method 1
(USP34)
Apparatus Chromatopac LC-10AS pump, ESA temperature-controlled a
and SPD-10 UV detector
(Shimadzu, Kyoto, Japan)
Stationary phase C18 Synergi Hydro 4 mm column (150  3.9 mm)a
Mobile phase Water: acetonitrile: H3PO4
85:15:0.1 (v/v)
Internal standard (IS) Phenacetin 
Flow rate (ml/min) 1 
Detection wavelength
(nm)
237 
Temperature (C) 25 C 
Injection volume (ml) 50 
Thalidomide retention
time (min)
18 (24 for IS) 
a Supplied by Phenomenex (Torrance, CA, USA).with a complementary anti-epistaxis therapy. The ultimate goal is
to sustain the effect obtained with the oral treatment after its
interruption. Three powders were prepared using as carriers b-CD
or the more hydrophilic HP-b-CD and SBE-b-CD, aiming to identify
the best performing thalidomide nasal powder with respect to
technological and biopharmaceutical features. In particular,
thalidomide dissolution and transport across rabbit nasal mucosa
and powder mucoadhesion were investigated. Then, as nasal drug
administration requires a device for dose delivery, the powder
formulations were combined with different devices to determine
the plume emission and deposition proﬁle in a model cast of the
human nose. Studying the effect of thalidomide nasal administra-
tion in HHT in humans was out of our scope here and will be the
subject of a future work.
2. Materials and methods
2.1. Materials
Thalidomide was purchased from Olon S.p.A. (Milan, Italy).
Phenacetin was obtained from Carlo Erba (Milan, Italy). b-cyclo-
dextrin and hydroxypropyl-b-cyclodextrin were supplied by
Roquette (Lestrem, France). Sulphobutylether-b-cyclodextrin
was kindly donated by CYDEX Pharmaceuticals (Lawrence, KS,
USA). Lecithin (LIPOID S45) was supplied by Lipoid AG (Steinhau-
sen, Switzerland). HPLC-grade acetonitrile was obtained from VWR
International S.r.l. (Milan, Italy). All other reagents and solvents
used were analytical grade.
2.2. Methods
2.2.1. HPLC assay
Thalidomide quantiﬁcation was performed by reverse phase
high performance liquid chromatography (HPLC) using the two
isocratic methods reported in Table 1. For drug quantiﬁcation in
powders and in phase solubility and dissolution rate samples, the
method complied with the USP 34 Thalidomide Ofﬁcial Mono-
graph. System suitability was assessed according to USP 34.
The method for determining thalidomide concentration in the
transport and mucoadhesion experiments was developed in-
house. This method was validated for repeatability (RSD 0.053%
and 0.063%, for area and retention time values respectively; n = 6
injections) and limits of quantiﬁcation and detection (LOQ 0.65 ng/
ml; LOD 0.22 ng/ml; n = 3 injections).Method 2
(in-house)
utosampler Agilent 1100 series with auto-sampler and UV–vis detector (Agilent,
Santa Clara, CA, USA)
C18 Luna 3 mm column
(150  4.6 mm)a
50 mM NaH2PO4: Acetonitrile
60:40 (v/v); pH 3
–
0.6
220
Ambient
40
4.8
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Phase solubility studies of thalidomide in the presence of
cyclodextrins were carried out in phosphate buffer solution 0.01 M
pH 5.0. Excess amounts of thalidomide (about 50 mg) were added
to 25 ml of buffer containing increasing concentrations of cyclo-
dextrins. Dispersions were magnetically stirred for 5 h, at room
temperature, then cleared through a 0.45 mm membrane ﬁlter and
assayed for thalidomide concentration with the HPLC Method 1
(Table 1).
2.2.3. Nasal powder manufacturing
Thalidomide-cyclodextrin powders were produced by a knead-
ing technique. 2.5 g of thalidomide and 7.0 g of cyclodextrin raw
materials were blended in a Turbula1 mixer (Type T2A; WAB,
Muttenz, Switzerland). The blend was transferred to a mortar and
kneaded with a solution of 0.5 g lecithin in 15 ml of ethanol. The
wet mass in the mortar was oven dried at 40 C up to complete
solvent evaporation. The dried product was forced through a
0.4 mm mesh sieve. This procedure allowed for the preparation of
three nasal powders containing thalidomide, lecithin and one of
the three cyclodextrins (b-CD, HP-b-CD or SBE-b-CD) in the ratio
of 25:5:70 (w/w).
2.2.4. Powder physico-chemical characterization
Differential Scanning Calorimetry (DSC) measurements were
performed on an indium calibrated DSC 821e calorimeter (Mettler
Toledo S.p.A., Milan, Italy). Accurately weighed samples (about
5 mg) were placed in aluminium pans, crimped and pierced.
Samples were heated at a rate of 10 C/min, from 30 to 300 C,
under a 100 ml/min ﬂow of dry nitrogen. The resulting thermo-
grams were analyzed with STARe Software to assess drug/excipient
interactions.
Powder X-ray diffractometry (PXRD) patterns were recorded
on a PW1050 diffractometer (Philips Analytical, Almelo, The
Netherlands), equipped with a curved graphite crystal, using Cu Ka
radiation. The scanning rate employed was 0.5min1 over a 2u
range of 2–50.
Morphology of powders was analyzed by scanning electron
microscopy (SEM) (Sigma HD, Carl Zeiss, Oberkochen, Germany) at
EHT 1.00 kV. A double-sided adhesive tape was placed on an
aluminium stub and a minimal amount of powder was dispersed
by gently tapping on the edge of the stub. The samples were
analyzed at different magniﬁcations after 30 min of depressuriza-
tion.
Particle size distribution of powders was measured using
laser light diffraction apparatus (Spraytec, Malvern Instruments
Ltd., Malvern, UK), by suspending powder aliquots in a 0.1%
solution (w/v) of Span 85 in cyclohexane. The analysis was
performed in a 100 ml cell under magnetic stirring, using a
300 mm lens.
Bulk and tapped volumes were determined with a 25 ml
graduated cylinder with 0.5 ml graduation marks according to Ph.
Eur., on powder samples weighing about 8–8.5 g. The bulk volume
was read after a gentle manual tapping of the cylinder. The tapped
volume was measured with a Tapped Density Tester (Erweka
GmbH, Heusenstamm, Germany) after tapping sequences of 1250
taps. From bulk and tapped volumes, the Compressibility Index
(or Carr Index, CI) was calculated according to the following
formula:
CI ¼ 100ðn0  nf Þ=n0
where vo is the bulk volume and vf is the tapped volume.
The static angle of repose was determined using the glass
funnel technique according to the Ph. Eur. 8th Ed.2.2.5. Biopharmaceutical characterization
2.2.5.1. In vitro dissolution rate. Thalidomide dissolution rate was
measured using a USP Apparatus II dissolution tester (Erweka
DT6R; Erweka GmbH, Heusenstamm, Germany). Samples of
thalidomide-cyclodextrin powders, equivalent to about 5–6 mg
thalidomide, were spread on the surface of the dissolution medium
(900 ml of PBS 0.01 M pH 5.0) at 37  0.5 C and stirred at 100 rpm.
At ﬁxed time points, samples ﬁltered through a 0.45 mm
membrane ﬁlter were analyzed for thalidomide concentration
by HPLC.
2.2.5.2. In vitro transport across excised nasal mucosa. Thalidomide
transport across excised rabbit nasal mucosa from the nasal
powders was studied in vitro using vertical Franz-type diffusion
cells (diffusion area: 0.58 cm2; Vetrotecnica, Padova, Italy). Rabbit
nasal mucosa was extracted from rabbit heads supplied by a local
slaughterhouse (Pola S.r.l., Finale Emilia, MO, Italy) on the day of
the experiment and transported to the lab in a refrigerated box. The
extraction procedure, completed within 2 h from the animal’s
death, has been described elsewhere (Balducci et al., 2013). Franz
cells were assembled with the tissue’s mucosal side facing the
donor. The receptor compartment was ﬁlled with 5 ml of a solution
composed of acetate buffer pH 5.0 and PEG 400 (50:50 v/v) to
assure sink conditions. The assembled cell was left to equilibrate
for 15 min at 37 C before introducing the formulation.
A saturated solution of thalidomide in 50 mM sodium acetate
buffer pH 5.0 was used as reference. One ml of this solution or 3 mg
of nasal powder (corresponding to 750 mg of thalidomide) was
introduced in the donor. With the powder, 100 ml of acetate buffer
pH 5.0 was added to the donor for powder dissolution. The cell was
protected from light during the experiment, which lasted 4 h
(Bortolotti et al., 2009). This experiment duration was consistent
with viability data in the literature for animal excised nasal tissue
in the course of in vitro studies: 3–4 h for bovine nasal mucosa and
up to 10 hours for isolated rabbit nasal mucosa with oxygenation
(Bechgaard et al., 1992; Schmidt et al., 2000). The receptor solution
was sampled only at the end of the experiment.
The residual thalidomide in the donor compartment was
quantitatively recovered with aliquots of mobile phase for
subsequent HPLC analysis (Method 2 in Table 1). Thalidomide
accumulating within the tissue thickness was then recovered by
comminuting the mucosa with a surgical blade and homogenizing
in 5 ml of water with Ultra-Turrax1 IKA (T10 basic model, IKA1-
Werke GmbH & Co. KG, Staufen, Germany) for 3 min. Two milliliters
of methanol were then added and homogenization continued for a
further 30 s to disrupt the cell membranes and dissolve the
thalidomide. The homogenate was centrifuged and the superna-
tant injected as such. Thalidomide amounts recovered from
receptor and donor compartments and the amount extracted
from the mucosa allowed for calculating the mass balance
(expressed as % of the thalidomide loaded in the donor). The
number of replicates for these studies was between 6 and 10.
2.2.5.3. In vitro mucoadhesion studies with rabbit nasal mucosa. The
biological material for these experiments was supplied to and
handled at the lab as described before. The nasal septum with the
mucosa layering on the cartilage was extracted from the rabbit’s
head and used as a surface for powder deposition. The septum with
the lining mucosa was ﬂat and rectangular (area 4.9  0.8 cm2;
mean  S.D., n = 7).
The septum in a Petri dish was introduced into a glass desiccator
at a relative humidity of 75–76% at room temperature (Wexler and
Hasegawa, 1954). About 20 mg of thalidomide-cyclodextrin
powder formulation were manually sprinkled on the whole
available mucosa surface. The dish was covered and left in the
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each ﬁlled with 15 ml of simulated nasal electrolyte solution
(SNES) at room temperature. SNES contained 8.77 mg/ml sodium
chloride, 2.98 mg/ml potassium chloride and 0.59 mg/ml calcium
chloride dehydrate (Castile et al., 2013). 20 min after powder
deposition, the nasal septum was pinched with tweezers on its
shorter side. Holding it ﬁrmly, the septum was continuously
submerged and withdrawn from the liquid in the tube for 1 min
with a frequency of 1 s in and 1 s out. The procedure was
repeated with the second and third tube for a total “washing time”
of 3 min.
The suspensions in the three tubes were centrifuged to separate
the solid (detached powder) from the supernatant (8000 rpm,
40 min). The sediments were treated with methanol to quantify
thalidomide in the powder physically detached from the mucosa
by the washing procedure, i.e., the non adhered thalidomide as
solid. The supernatants were also analyzed by HPLC Method 2
(Table 1) to quantify the fraction of thalidomide solubilized by the
SNES, i.e., the non adhered thalidomide as solution. Finally, the
mucosa with the residual powder attached was treated with
methanol to dissolve thalidomide for quantiﬁcation (adhered
thalidomide).
Mucoadhesion was expressed as percent of adhered thalido-
mide versus the total thalidomide recovered. For each powder
formulation, at least 3 replicates were carried out.
2.2.6. Powder and device combination (delivery and deposition in
nasal cast)
The amount of nasal powder emitted upon device actuation was
measured and pictures of the delivery sequence were taken
(Buttini et al., 2012; Russo et al., 2004). Three devices were
employed: one active single dose (MIAT, Milan, Italy), one active
multi-dose (Teijin Ltd., Tokyo, Japan) and a passive bi-dose (Aptar,
Louveciennes Cedex, France) device. MIAT and Aptar devices are
designed for delivering a dose of powder pre-metered in a size 3
capsule and in a bi-dose blister reservoir respectively. Both were
loaded with approximately 20 mg of powder, corresponding to a 5-
mg thalidomide dose. The Teijin device has an internal reservoir for
the powder bulk and a metering chamber. MIAT and Teijin devices
have a squeezable rubber bulb manually actuated by an operator to
generate the airﬂow. Since the Aptar device is breath-actuated,
15 L/min airﬂow was drawn through it for 2 s using a vacuum pump
to extract the powder from the reservoir. Quantitative delivery of
the powder from the insufﬂator was determined by weighing the
insufﬂator before and after each actuation. Sequences of images of
the powder plume during the actuation were recorded using a
video camera (Panasonic HDC-TM 700, Panasonic Corp., Kadoma,
Japan).
Plume deposition in a human nasal model was carried out using
a silicon cast (Teijin Pharma Ltd. Tokyo, Japan) (Bettini et al., 1999).
Insufﬂation with the same three devices was performed in oneFig. 1. Phase solubility diagrams of thalidomide in presence of (a) b-CD, (b) HP-b-CD an
(R2 = 0.99), (b) y = 0.19209 + 0.01669 x (R2 = 0.99) and (c) y = 0.19313 + 0.03153 x (R2 = 0.97nostril of the assembled nasal cast. The nasal cavities were then
separated and pictures were taken.
2.2.7. Powder stability study
The stability of thalidomide-cyclodextrin powders was studied
in the short term, namely for 3 months of storage at 25 C/60% RH
and for 1 month at 40 C/75% RH. About 20 mg of each formulation,
corresponding to a 5-mg thalidomide dose, were stored in size 3
HPMC capsules and tested at ﬁxed time points for thalidomide
content, in vitro dissolution rate and powder insufﬂation using the
single-dose MIAT device.
2.2.8. Statistical analysis
Statistical analysis of data was performed by applying an
unpaired two-tailed Student’s t-test. Signiﬁcance was accepted at p
values < 0.05.
3. Results and discussion
Nasal powders of thalidomide have to induce a local anti-
angiogenic action on the microvasculature of the nasal mucosa
compromised by HHT. To exert a local effect or to have drug
absorption, the formulation must enable drug dissolution in the
small volume of liquid lining the mucosa. On site powder
dissolution leads to local drug saturation concentration. Thalido-
mide is very slightly soluble in water and the raw material does not
wet easily. Thus, it was decided to introduce a cyclodextrin in the
formulation as a solubility enhancer (Kale et al., 2008; Kratz et al.,
2012; Krenn et al., 1992).
In order to establish the optimal thalidomide to b-CD, HP-b-CD
or SBE-b-CD ratio in the nasal product, phase solubility studies
were carried out in phosphate buffer pH 5.0 at 25 C. This buffer
was used as solvent because thalidomide is more stable at acidic
pH. All three b-CDs increased thalidomide solubility, which was
about 42 mg/ml in the absence of cyclodextrin. The phase solubility
diagrams show that thalidomide solubility increased linearly as a
function of cyclodextrin concentration (Fig. 1). The relationship
between cyclodextrin and thalidomide concentrations led to an AL-
type diagram, which is typical of 1:1 complexes. Calculated
stability constants were 313 M1, 105 M1 and 201 M1 for b-CD,
HP-b-CD and SBE-b-CD respectively. The complexation efﬁciency
of the three cyclodextrins, whose inverse value expresses the
number of CD molecules in solution that form a 1:1 complex with
thalidomide, was 0.05 for b-CD, 0.017 for HP-b-CD and 0.032 for
SBE-b-CD (Loftsson et al., 2005).
3.1. Manufacturing and physico-chemical characterization of
thalidomide/cyclodextrin powders
b-CD, HP-b-CD and SBE-b-CD were used for the formulation of
the nasal powder because they all enhanced thalidomide solubilityd (c) SBE-b-CD (mean values  S.D.; n = 3). Linear ﬁtting: (a) y = 0.16626 + 0.04830 x
).
Fig. 2. DSC thermograms of (a) thalidomide raw material, (b) b-CD nasal powder,
(c) HP-b-CD nasal powder and (d) SBE-b-CD nasal powder.
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were produced by kneading and contained 25% thalidomide (w/w)
and 70% cyclodextrin (w/w) with the objective of having 5 mg of
drug in 20 mg of powder to insufﬂate. This meant that the molar
ratio between thalidomide and the CD was 1:0.64, 1:0.53 and
1:0.51 respectively for b-CD, HP-b-CD and SBE-b-CD. The
formulation also contained 5% (w/w) lecithin, which was added
during kneading as ethanol solution to improve the wettability of
thalidomide.
In order to verify whether a complex was formed during the
kneading process, the powders were studied by differential
scanning calorimetry in comparison with crystalline thalidomide
(THAL) raw material (Fig. 2). The THAL raw material thermogram
showed a sharp endothermic peak at 276 C corresponding to the
drug melting point. The thermograms of the thalidomide/CD
powders showed a broad endothermic band around 100 C,
corresponding to the release of water from the cyclodextrin cavity.
The melting peak of thalidomide was still present, although muchFig. 3. SEM images of (a) thalidomide raw material, (b) b-CD nasal posmaller and shifted to lower temperatures, likely due to an
interaction of the two compounds in the mixture. In fact, the
enthalpy of fusion for the pure drug was 158 J g1, whereas it was
44.32 J g1, 21.92 J g1 and 133.94 J g1 respectively for THAL/
b-CD, THAL/HP-b-CD and THAL/SBE-b-CD. This last value should
not be considered as fully reliable, being affected by the
degradation peak of SBE-b-cyclodextrin that superposed to the
THAL melting peak.
Additional evidence of an interaction occurring between
thalidomide and cyclodextrins was obtained by PXRD analysis
(Supplementary Material). Thalidomide raw material peaks were
sharp and intense, conﬁrming its crystalline nature. In contrast,
thalidomide kneaded with the cyclodextrins showed less intense
peaks.
Powder particle size, packing and ﬂow are key properties in
view of nasal dosage form manufacturing, delivered dose
uniformity, aerodynamic behaviour during insufﬂation, dissolu-
tion rate and interaction with the wet mucosa. Particle size analysis
by laser diffraction showed a mean volume diameter (Dv0.5)
between 13 and 22 mm for all powders (Table 2). This size was also
conﬁrmed by SEM analysis (Fig. 3). The particle shape of kneaded
products appears as agglomerates with sharp edges, resulting from
the sieve comminution after drying. Nevertheless, this non
spherical morphology did not negatively affect powder ﬂow and
packing. Bulk density and repose angle values of these nasal
powders allowed for classifying the formulations containing b-CD
and HP-b-CD as free-ﬂowing according to the Pharmacopoeia
(Table 2). The SBE-b-CD nasal powder had inferior ﬂow properties
and looser packing.
3.2. Nasal powder stability
For thalidomide-cyclodextrin powders stored in size 3 HPMC
capsules at 25 C/60% RH for 3 months and at 40 C/75% RH for 1
month, b-CD powder and HP-b-CD powder remained stable in all
conditions with respect to thalidomide content. Similarly, SBE-
b-CD powder did not show a signiﬁcant decrease in thalidomidewder, (c) HP-b-CD nasal powder and (d) SBE-b-CD nasal powder.
Table 2
Particle size and powder ﬂow of thalidomide/cyclodextrin powders (n = 3).
Nasal Powder Dv0.1
(mm)
Dv0.5
(mm)
Dv0.9
(mm)
Bulk Density
(g/ml)
Tapped Density
(g/ml)
Compressibility
Index
Angle of repose
b-CD 3.1  0.1 19.2  0.5 58.5  2.9 0.55  0.01 0.70  0.01 20.0 28.5  1.2
HP-b-CD 3.2  0.2 18.1  2.1 61.6  5.7 0.60  0.01 0.80  0.01 20.0 21.8  2.6
SBE-b-CD 3.5  0.3 21.2  3.5 61.1  10.3 0.48  0.01 0.60  0.01 23.3 34.6  0.7
234 G. Colombo et al. / International Journal of Pharmaceutics 514 (2016) 229–237content, despite its colour turning to pale yellow after storage at
40 C. Stability was also conﬁrmed with respect to in vitro
dissolution rate and powder delivery.
3.3. Biopharmaceutical characterization
3.3.1. In vitro thalidomide nasal powder dissolution rate
Dissolution rate of thalidomide nasal powders was measured in
vitro in an aqueous medium at pH 5.0 over 2 h (Goosen et al., 2002;
Pereira et al., 2013; Schumacher et al., 1965). These experiments
were carried out with the purpose of comparing the dissolution
behaviour of the nasal powders in sink conditions for the quality
assessment of solid preparations. Thalidomide raw material, i.e.,
the solid material before the formulation process, was used as
reference.
In these conditions only 46.0  0.1% of thalidomide raw
material dissolved in 1 h, reaching 72.0  0.9% at the end of the
second hour (Fig. 4). It was observed that during the ﬁrst minute
drug powder ﬂoated on the dissolution medium surface, owing to
its difﬁcult wettability. In contrast, kneaded powders containing
cyclodextrins together with lecithin dissolved more rapidly,
reaching 84 1%, 99  2% and 93  2% respectively of thalidomide
in solution after 60 min. for the powder containing b-CD, HP-b-CD
and SBE-b-CD. This improvement in drug dissolution rate had two
main explanations. Firstly, solid state analysis of the powders
showed that thalidomide and cyclodextrins partially interacted.
This interaction at the molecular level increased the drug solubility
in aqueous environment (as demonstrated in the phase solubility
studies). The second positive contribution to thalidomide dissolu-
tion rate came from lecithin, owing to its surface-active properties.
The positive effect of lecithin on wettability increased the powder
surface interacting with the solvent.Fig. 4. Dissolution proﬁles of () thalidomide raw material, (&) b-CD nasal
powder, (4) HP-b-CD nasal powder and (^) SBE-b-CD nasal powder (mean  S.D.;
n = 3).3.3.2. In vitro thalidomide transport across rabbit nasal mucosa
In vitro THAL transport across excised rabbit nasal mucosa in a
4-h experiment was negligible from all powders, as well as from
the thalidomide saturated solution. Having observed that trans-
mucosal diffusion was very low, if not absent, the THAL
concentration in the receptor compartment was measured only
at the end of the experiment. THAL concentration was above LOQ
only in the experiments with the thalidomide saturated solution
and the nasal powder containing b-CD (0.09  0.10 mg/5 ml and
0.13  0.09 mg/5 ml respectively). Independently of the formula-
tion, more than 80% of the loaded thalidomide remained in the
donor. The thalidomide present in the mucosa at the end of the
permeation experiment was extracted from the tissue sample used
as barrier. The amounts recovered are shown in the bar graph of
Fig. 5.
Any possible drug degradation occurring during the permeation
was assessed by determining the thalidomide mass balance after
all transport experiments (Table 3). The mass balance for the
powder formulations was higher than 90%, indicating that the
experimental variability and drug stability were under control. The
mass balance below 90% for the saturated solution has to take into
account that the amount of thalidomide loaded in the donor was
much lower than with the powders (65 vs 750 mg respectively).
In summary, the transport experiments showed that thalido-
mide was poorly diffused across the nasal epithelium, remaining to
a certain extent in the tissue. The negligible transport across the
mucosa is a pivotal result with respect to topical application,
because it reduces the likelihood of thalidomide being signiﬁcantly
absorbed from the nasal cavity into the systemic circulation. In full
awareness that these in vitro data cannot substitute the
bioavailability study following nasal administration, in any case
they indicate that in vivo systemic absorption may not be clinically
relevant. In fact, these data were collected after 4 h of contact
between formulation and mucosa, whereas residence time inside
the nasal cavity, even for a solid formulation, may not be as long.Fig. 5. Amounts of thalidomide extracted from the mucosa at the end of the 4-h
diffusion experiment (thalidomide loaded at time zero: 65 mg for the saturated
solution, 750 mg for the powders; mean  S.D., n = 6–10).
Table 3
Mass balance from in vitro transport experiments in Franz cells (mean  S.D.;
number of replicates in parentheses).
Formulation Mass balance (%)
Saturated solution (10) 83  7
b-CD (6) 96  6
HP-b-CD (6) 91  2
SBE-b-CD (7) 96  2
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ture of the nasal mucosa in HHT is the target of the local application
of thalidomide. Thus, thalidomide accumulation within the tissue
is favourable to its local action.
Comparing the nasal powder formulations, the b-CD powder
led to the greatest THAL accumulation within the tissue.
b-cyclodextrin is known as an absorption enhancer in nasal drug
delivery (Marttin et al., 1998). The mechanism underlying this
action has been related to the interaction with the nasal epithelial
membranes and transient opening of tight junctions. Several
studies indicate different enhancing properties of b-cyclodextrin
and derivatives depending on the substituting moiety. In general,
methylated derivatives appeared more effective compared to
hydroxypropyl-b-cyclodextrin with respect to nasal absorption of
drugs (Merkus et al., 1999). The higher absorption enhancing effect
of b-cyclodextrin compared to the other derivatives was also seen
from the traces of thalidomide detected in the receptor compart-
ment.
3.3.3. Mucoadhesion
Thalidomide interaction with cyclodextrins improved powder
mucoadhesion compared to the drug raw material as powder. In
this work the mucoadhesion was measured by a methodology
consisting in washing, in controlled conditions with a simulated
nasal ﬂuid (SNES), a sample of nasal mucosa on which the nasal
powder had been previously deposited. The results are expressed
as mean values  standard deviation of replicates carried out by
two operators. The obtained variability of the individual data is
consistent with a reproducible procedure.
For the three formulations, the average percentage of THAL
retained on the mucosa surface after the washing procedure with
the simulated nasal ﬂuid (ADHERED) and the drug amounts not
retained and recovered in the removed solid or dissolved in the
ﬂuid (NON ADHERED) are shown in Fig. 6. To reveal a possible time
dependency of mucoadhesion, the product was removed from theFig. 6. Percentage of thalidomide retained on (ADHERED) and removed from the mucosa
non adhered amounts were recovered as dispersed solid or in solution in the washing ﬂumucosa by washing three times at 1 min intervals. It was found that
the lower the thalidomide dissolution rate in water, the greater the
mucoadhesion. Indeed, 50% of the b-cyclodextrin powder was still
retained on the mucosa surface after the washing. This was the
same powder enabling the highest thalidomide accumulation
within the mucosal tissue (see Fig. 5). As the more hydrophilic HP-
b-CD and SBE-b-CD increased wettability and dissolution rate in
aqueous media, the corresponding nasal powders more easily lost
the contact with the mucosa and were removed. The respective
adhered amounts were not signiﬁcantly different (p = 0.16). The
solid material physically detached from the mucosa remained
dispersed or dissolved in the washing liquid phase. In fact, between
4% (b-CD powder) and 16% (HP-b-CD powder) of removed
thalidomide was found in solution. Thus, dissolution by the
washing ﬂuid was mostly relevant for the most soluble HP-b-CD
powder (p < 0.05 vs SBE-b-CD powder).
From a kinetic point of view, most powder detachment and
dissolution occurred during the ﬁrst minute of washing, in
particular for the HP-b-CD and SBE-b-CD powders (80  5% and
82  8% respectively; p = 0.23). Then, between 3% and 6% of
thalidomide was washed away during the second and third
minute, without signiﬁcant differences between the above two
powders. In contrast, a time-dependency of mucoadhesion was not
found for the b-CD powder, whose total non adhered fraction was
mainly recovered as dispersed solid in SNES (Supplementary
material).
3.4. Powder and insufﬂation device combination
A nasal drug product is a typical combination product,
comprising formulation and device for its delivery. The choice of
a proper device is driven by the therapy requirements and target
deposition site, as well as the characteristics of the product to be
administered. For the local action desired in HHT, thalidomide
deposition should cover the maximum mucosal surface for the
longest possible time. Moreover, the device should effectively
deliver the powder, while limiting its dispersion in the environ-
ment. In this regard, in the case of thalidomide a passive device
may be preferable.
In order to propose a nasal device tailored to the investigated
formulation, powder delivery and deposition were tested with
three commercially available devices with different insufﬂation
mechanisms, namely an active single-dose (MIAT), an active multi-
dose (Teijin) and a disposable passive bi-dose (Aptar) one. The surface (NON ADHERED) after 3 min washing in 45 ml of simulated nasal ﬂuid. The
id; mean  S.D., n = 3–4. *p < 0.05 according to unpaired two-tailed Student’s t-test.
Table 4
Mean delivered powder amount (mg) from Aptar, MIAT and Teijin devices
(mean  S.D., n = 10).
Powder Aptar MIAT Teijin
b-CD 20.4  1.2 19.0  0.7 18.5  0.6
HP-b-CD 21.0  1.7 21.0  0.7 21.7  1.2
SBE-b-CD 20.4  1.2 17.6  1.9 13.9  0.8
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i.e., 4, 0.6 and 15 L/min respectively. We wanted to investigate
whether and in what way the actuation mode and airﬂow affected
powder dose delivery and deposition site inside the nose cast.
Table 4 presents the powder amounts delivered upon actuation
of each of the considered devices. The reported values are the mean
of ten shots. Capsules or blisters used in MIAT and Aptar contained
20 mg of powder, corresponding to a thalidomide dose of 5 mg. The
delivered dose for the multi-dose device (Teijin) was the average of
ten consecutive metered actuations.
Powder delivery depended on both formulation technological
properties and device airﬂow during insufﬂation. With MIAT and
Teijin devices the delivered dose was in line with the powder
repose angle values (HP-b-CD > b-CD > SBE-b-CD; see Table 2). The
differences in delivered amount coming from the powder ﬂow
characteristics were levelled down with the Aptar device. This was
reasonably due to the higher operating airﬂow. The powder
formulated with HP-b-CD was the only one quantitatively emitted
without signiﬁcant differences among the devices. The values were
within the limits ( 15% of the label claim) of the guideline on the
pharmaceutical quality of inhalation and nasal products (EMA,
2006).
Picture sequences of emitted plumes show that powder
delivery from the devices was completed in less than one second
(Supplementary Material). The plume development with Aptar
was difﬁcult to visualize owing to the experimental need to conﬁne
it in an air drawing tube connected with the nose adapter. The
combined effect of formulation and device variables was reﬂected
in the plume shape. The more ﬂowable powders containing b-CD
and HP-b-CD led to closely packed plumes. In contrast, the more
cohesive SBE-b-CD powder generated less dense clouds, conﬁrm-
ing a less efﬁcient powder delivery for this formulation.
Taking into account the disease, the target deposition site and
desired intranasal distribution of the drug, a ﬁnal study was carried
out generating the powder plume with the three insufﬂators
directly into a silicone human nasal cast. The cast allowed for
visualizing differences among the distribution of the powders in a
human nasal cavity. Only the HP-b-CD powder was considered for
this study because the delivered amount was the same for all
devices (see photographs of deposition patterns in the Supple-
mentary Material). Each device gave rise to a different degree of
coverage of the various regions of the nasal cavity. During the
experiment, we qualitatively observed that the Aptar and Teijin
devices deposited the powder more homogeneously in the
vestibular, pre-turbinate and turbinate regions, whereas in the
MIAT device larger particles were deposited in the turbinate
region.
4. Conclusions
The nasal powder formulation of thalidomide with lecithin and
b-cyclodextrin or its derivatives hydroxypropyl-b-cyclodextrin or
sulphobutylether-b-cyclodextrin gave rise to stable products with
suitable technological properties for nasal insufﬂation. From a
biopharmaceutical point of view, the improved dissolution rate
compared to that of the raw material made thalidomide promptly
available in the aqueous nasal environment at a concentrationgiving rise to an accumulation in the mucosa, with limited
transmucosal transport. This in vitro observation suggests a low
likelihood of signiﬁcant systemic absorption. The topical action on
bleeding could beneﬁt from the poor absorption and from the fact
that about 2–3% of the thalidomide applied on the mucosa in vitro
was accumulated within the tissue, particularly with the b-CD
nasal powder. Furthermore, residence time in the nasal cavity may
be prolonged by the mucoadhesive action provided by this nasal
powder. Considering the nasal cavity coverage, deposition of b-CD
nasal powder was predicted as more efﬁcient when using a passive
device, i.e., a device delivering the powder only when the patient
inhales through it. An additional advantage of this actuation mode
could be the limited powder dispersion in the environment around
the patient. This is relevant with a formulation containing
thalidomide. Thus, in nose telangiectasia, nasal powders could
enable topical thalidomide treatment as a complement to systemic
oral administration for maintenance therapy, thus contributing to
a safer re-positioning of an effective active drug.
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